Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Czechia

Marie Skłodowska-Curie Action · Running

ZwitterMPs Stabilizing pharmaco-active Membrane proteins with Zwitterionic polymers and leveraging Surface Plasmon Resonance as an Analytical platform

Coordinator
Fyzikalni Ustav Av Cr, Vvi, Czechia
Runs
2 March 2026 to 1 March 2028
Status
Running
EU funding
€208k
Total cost
—
Partners
3 organisations in 3 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101211954

What the project is doing

In the project's own words, from its summary on CORDIS.

Membrane proteins, particularly G-protein-coupled receptors (GPCRs), represent 25-30% of current drug targets. Among them, metabotropic glutamate receptor (mGluR), a Class C and group 1 type GPCR, is emerging as an attractive therapeutic target for various neurological and psychiatric disorders such as Alzheimer’s disease, Parkinson's disease, autism spectrum disorder, schizophrenia, and neuropathic pain. Despite the availability of its complete structure, biophysical characterization and drug discovery efforts targeting mGluR have been hindered by the challenges in obtaining stable, active conformations of this receptor for in-vitro studies.

To overcome this impediment, we will utilize amphiphilic zwitterionic polymers, for stabilizing mGluR. Carefully synthesizing copolymers can mimic the native lipid environment and maintain the receptor's structural and functional integrity. Zwitterionic polymers, with their unique molecular architecture featuring both anionic and cationic groups, structure surrounding water molecules, creating super-hydrophilic surfaces ideal for stabilizing membrane proteins with exposed hydrophobic domains.

To evaluate this stabilization strategy, we first aim to employ the label-free bio-analytical technique of surface plasmon resonance to immobilize the mGluR-polymer complex. Secondly, we will investigate binding kinetics, affinities, and allosteric modulation of mGluR1 receptor to obtain valuable insights into protein-drug interactions. We anticipate this innovative strategy will address the existing challenges in stabilizing mGluR, offering improved stability, reduced complexity, cost-effectiveness, and higher yields over conventional methods.

Moreover, it will accelerate drug screening practices targeting mGluR and other challenging membrane protein targets in the long run, thereby contributing to developing novel therapeutics for neurological and psychiatric disorders.

Topics

Who is involved

OrganisationCityCountryRole
Fyzikalni Ustav Av Cr, VviPraha 8CzechiaCoordinator
Universitaet GrazGrazAustriaAssociatedpartner
National Central UniversityTaoyuan CityTWAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI